Polymer-semaxanib moiety conjugates
View Patent ↗The invention relates to (among other things) polymer-semaxanib moiety conjugates and related compounds. A compound of the invention, when administered by any of a number of administration routes, exhibits advantages over the semaxanib moiety in unconjugated form.
1. A method of treating a glioma comprising:
administering a therapeutically effective amount of a compound to a subject in need thereof, the compound having a formula:
or pharmaceutically acceptable salts thereof wherein:
X is a spacer moiety selected from a single bond, an ether, an amide, a urethane, an amine, a thioether, a carbamate, an ester, a carbonate, and a urea linkage; and
n is an integer from 3 to 10.
2. The method of claim 1 , wherein said administering comprises orally administering the compound.
3. The method of claim 2 , wherein said orally administering comprises administering the compound in the form of a tablet, caplet, capsule, gel capsule, troche, dispersion, suspension, solution, elixir, or syrup.
4. The method of claim 1 , wherein said administering comprises parenterally administering.
5. The method of claim 4 , wherein said parenterally administering is selected from subcutaneous, intravenous, intra-arterial, intraperitoneal, intramuscular, and infusion.
6. The method of claim 1 , wherein said administering comprises administering about 0.001-1000 mg/day of the compound.
7. The method of claim 1 , wherein said administering comprises administering the compound five times a day, four times a day, three times a day, twice daily, once daily, three times weekly, twice weekly, once weekly, twice monthly, or once monthly.
8. The method of claim 1 , wherein the compound has the formula:
or a pharmaceutically acceptable salt thereof.
9. The method of claim 1 , wherein the glioma is mediated by abnormal vascular endothelial growth factor (VEGF) receptor tyrosine kinase activity.
10. The method of claim 1 , wherein the glioma is a glioblastoma.
11. The method of claim 1 , wherein said administering comprises administering about 0.01-750 mg/day of the compound.
12. The method of claim 1 , wherein said administering comprises administering about 0.10-500 mg/day of the compound.